BioCardia’s (BCDA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of BioCardia (NASDAQ:BCDA) in a research report released on Wednesday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

BioCardia Price Performance

Shares of BCDA stock opened at $1.97 on Wednesday. The firm has a 50-day moving average of $2.30 and a 200-day moving average of $2.76. BioCardia has a one year low of $1.63 and a one year high of $10.79. The company has a market cap of $9.02 million, a P/E ratio of -0.47 and a beta of 1.25.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.